Edition:
United States

Viking Therapeutics Inc (VKTX.OQ)

VKTX.OQ on NASDAQ Stock Exchange Capital Market

10.61USD
1:33pm EDT
Change (% chg)

$-0.47 (-4.24%)
Prev Close
$11.08
Open
$10.96
Day's High
$11.06
Day's Low
$10.07
Volume
421,773
Avg. Vol
534,284
52-wk High
$13.40
52-wk Low
$0.88

Chart for

About

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company's clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip... (more)

Overall

Beta: --
Market Cap(Mil.): $647.44
Shares Outstanding(Mil.): 58.43
Dividend: --
Yield (%): --

Financials

  VKTX.OQ Industry Sector
P/E (TTM): -- 248.83 34.14
EPS (TTM): -0.65 -- --
ROI: -44.80 -5.25 13.10
ROE: -47.16 -6.83 15.09

BRIEF-Viking Therapeutics Q1 Loss Per Share $0.08

* VIKING THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

May 09 2018

BRIEF-Viking Therapeutics Q4 Loss Per Share $0.14

* VIKING THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Mar 07 2018

BRIEF-Viking Therapeutics - Pricing Public Offering Of 11 Mln Shares At $5 Per Share

* VIKING THERAPEUTICS ANNOUNCES PRICING OF $55.0 MILLION PUBLIC OFFERING OF COMMON STOCK

Feb 02 2018

BRIEF-Viking Therapeutics Announces Proposed Public Offering Of Common Stock

* VIKING THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

Feb 01 2018

Earnings vs. Estimates